Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II trial of nivolumab with alternatively scheduled ipilimumab in first-line advanced or metastatic renal cell carcinoma
2017-001476-33Phase 2Unknown
- Sponsor
- University of Leeds
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of nivolumab and ipilimumab in renal cell carcinoma (RCC) and clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by University of Leeds. Primary endpoints: Grade 3 or 4 adverse reactions within 12 months and Progression-free at 12 months. Status: unknown.
02
Drugs
nivolumabipilimumab
03
Conditions
renal cell carcinoma (RCC)clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2017-001476-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001476-33.